---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-005594"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:21:13.023962+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyadic completes dosing in Phase 1 COVID-19 vaccine trial; no SAEs, Q2 data update expected

## Summary
- DYAI-100 COVID-19 booster vaccine trial: dosing of low and high dose groups completed Feb 2023.
- No serious adverse events reported; vaccine well tolerated to date.
- Initial safety and antibody response update expected in Q2 2023.
- First human test of C1-cell platform for vaccines; CEO notes increased interest from academia/industry.

## SEC filing metadata
- accession: 0001437749-23-005594
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774923005594/0001437749-23-005594-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774923005594/dyai20230306_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-005594
- JSON: https://secwatch.observer/filing/0001437749-23-005594.json
- Plain text: https://secwatch.observer/filing/0001437749-23-005594.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.